Sustained hypoglycemia with therapeutic use of repaglinide
- 18 Downloads
Repaglinide is a short-acting insulin secretagogue used for the reduction in postprandial glucose levels in diabetic patients. It has a favorable safety profile with a low risk of hypoglycemia. Prolonged hypoglycemia appears exceptional due to the short serum elimination half-life.
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Philippe Hantson, Pierre-François Laterre, Vincent Haufroid and Souleiman El Balkhi. The first draft of the manuscript was written by Philippe Hantson, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare they have no conflict of interest.
Human and animal rights disclosure
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
A written informed consent was obtained from the patient.
Sources of funding